Vincent J. Willey
Research Subjects
Vincent J. Willey has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Alex C. Spyropoulos
Clinical Thrombosis Center, Lovelace Health System, Albuquerque, New Mexico, USA
1 shared publicationAlex Ganetsky
Hospital of the University of Pennsylvania, Philadelphia, PA
1 shared publicationAnn M Galla
1 shared publicationAnna E. Wallace
HealthCore, Wilmington, Delaware
1 shared publicationAsif Shaikh
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut
1 shared publicationBenjamin P Soule
Clinical Development & Outcomes Research, Novo Nordisk Inc, Plainsboro, New Jersey, USA
1 shared publication
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Advances in Therapy
- p. 1-9
Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments
Introduction: Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns. Methods: In this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD ® ) were used to identify new ruxolitinib cream users aged ≥ 12 years between October 1, 2021 and July 31, 2022. The 6 months prior to the index date (first claim for ruxolitinib cream) comprised the baseline period. The 18-month follow-up period was divided into months 1–6, 7–12, and 13–18 to evaluate short- and long-term effects of ruxolitinib cream on AD treatment patterns. Results: A total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1–19). By months 13–18 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy ( n = 231), 35.5% did not receive biologics during months 13–18 of follow-up. Additionally, among patients without baseline biologic use ( n = 1038), > 90% remained off biologics. Conclusion: Use of both topical and systemic AD therapies, including biologics, decreased over 18 months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.
- 5 August 2026
- Published by Springer Nature in Advances in Therapy
- p. 1-9
Open AccessReal-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments
Introduction: Ruxolitinib cream has demonstrated efficacy and safety in patients aged ≥ 2 years with mild to moderate atopic dermatitis (AD) in clinical trials. Early real-world data have demonstrated results consistent with clinical trial observations and have indicated that initiation of ruxolitinib cream may reduce the need for other AD therapies, both topical and systemic. This analysis investigated the longer-term (18-month) effect of ruxolitinib cream on AD treatment patterns. Methods: In this retrospective, observational study, US claims data from the Healthcare Integrated Research Database (HIRD ® ) were used to identify new ruxolitinib cream users aged ≥ 12 years between October 1, 2021 and July 31, 2022. The 6 months prior to the index date (first claim for ruxolitinib cream) comprised the baseline period. The 18-month follow-up period was divided into months 1–6, 7–12, and 13–18 to evaluate short- and long-term effects of ruxolitinib cream on AD treatment patterns. Results: A total of 1269 patients were included in the analysis. The mean (SD; range) number of ruxolitinib cream fills during the 18-month follow-up period was 2.4 (2.3; 1–19). By months 13–18 of follow-up, claims for topical corticosteroids, topical calcineurin inhibitors, and topical PDE4 inhibitors were reduced from baseline by 52%, 63%, and 70%, respectively. Use of oral corticosteroids was reduced by 28%, with a 32% reduction in the mean cumulative prednisone-equivalent dose. Among patients with baseline biologic AD therapy ( n = 231), 35.5% did not receive biologics during months 13–18 of follow-up. Additionally, among patients without baseline biologic use ( n = 1038), > 90% remained off biologics. Conclusion: Use of both topical and systemic AD therapies, including biologics, decreased over 18 months following initiation of ruxolitinib cream. These data suggest that ruxolitinib cream may reduce the need for additional topical therapies and limit escalation to systemic therapies for adults and adolescents with AD.
- Open Access
- 3 May 2023
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 11 (3) , e003206
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
Introduction: Once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 analog, is approved in the USA as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes (T2D) to improve glycemic control and reduce the risk of major adverse cardiovascular events in people with T2D and established cardiovascular disease. The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) phase III clinical trial program demonstrated the efficacy and safety of once-weekly subcutaneous semaglutide; however, determining its effectiveness in a real-world setting could support decision-making by clinicians, payers and policy makers in routine clinical practice. Research design and methods: SEmaglutide PRAgmatic (SEPRA) is an ongoing open-label, randomized, pragmatic clinical trial designed to compare the effects of once-weekly subcutaneous semaglutide versus standard of care in US health-insured adults with T2D and physician-determined inadequate glycemic control. The primary end point is the proportion of participants achieving glycated hemoglobin (HbA1c) 2. Mean diabetes duration was 7.4±6.0 years and mean HbA1c was 8.5±1.6%. At baseline, concomitant antidiabetes medications included metformin, sulfonylureas, sodium-glucose co-transporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors. The majority of participants had hypertension and dyslipidemia. The trial design was self-assessed using the PRagmatic Explanatory Continuum Indicator Summary-2 tool by the study steering group and was scored 4–5 in all domains suggesting a highly pragmatic study. Conclusions: SEPRA, a highly pragmatic ongoing study, will provide data on the effects of once-weekly subcutaneous semaglutide in a real-world setting when used during routine management of T2D. Trial registration number: NCT03596450. Trial registration number
- 3 May 2023
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 11 (3) , e003206
Open AccessStudy design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
Introduction: Once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 analog, is approved in the USA as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes (T2D) to improve glycemic control and reduce the risk of major adverse cardiovascular events in people with T2D and established cardiovascular disease. The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) phase III clinical trial program demonstrated the efficacy and safety of once-weekly subcutaneous semaglutide; however, determining its effectiveness in a real-world setting could support decision-making by clinicians, payers and policy makers in routine clinical practice. Research design and methods: SEmaglutide PRAgmatic (SEPRA) is an ongoing open-label, randomized, pragmatic clinical trial designed to compare the effects of once-weekly subcutaneous semaglutide versus standard of care in US health-insured adults with T2D and physician-determined inadequate glycemic control. The primary end point is the proportion of participants achieving glycated hemoglobin (HbA1c) 2. Mean diabetes duration was 7.4±6.0 years and mean HbA1c was 8.5±1.6%. At baseline, concomitant antidiabetes medications included metformin, sulfonylureas, sodium-glucose co-transporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors. The majority of participants had hypertension and dyslipidemia. The trial design was self-assessed using the PRagmatic Explanatory Continuum Indicator Summary-2 tool by the study steering group and was scored 4–5 in all domains suggesting a highly pragmatic study. Conclusions: SEPRA, a highly pragmatic ongoing study, will provide data on the effects of once-weekly subcutaneous semaglutide in a real-world setting when used during routine management of T2D. Trial registration number: NCT03596450. Trial registration number
- Open Access
- 1 December 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (12) , 2808-2810
Observational Evaluations of Disease Management Programs for Diabetes: The Proof Is in the Concept
Despite the introduction of multiple novel therapeutics over the past two decades, rates of control in type 2 diabetes (T2D) and its comorbidities remain subopt
- 1 December 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (12) , 2808-2810
Open AccessObservational Evaluations of Disease Management Programs for Diabetes: The Proof Is in the Concept
Despite the introduction of multiple novel therapeutics over the past two decades, rates of control in type 2 diabetes (T2D) and its comorbidities remain subopt
- Open Access
- 1 May 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (5) , 808-821
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
- 1 May 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (5) , 808-821
Open AccessReal-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
- 1 February 2019
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 25 (2) , 205-217
Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and is associated with substantial economic burden. There is a lack of data regarding COPD outcomes and costs in a real-world setting, particularly by Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity. To (a) characterize a commercially insured U.S. population with COPD and (b) assess prevalence of exacerbations, health care resource utilization (HCRU), costs, and treatment patterns in a cohort of patients with confirmed COPD, overall and stratified by GOLD stage. This retrospective observational cohort study used administrative claims data from the HealthCore Integrated Research Database to identify patients with ≥ 1 inpatient, emergency room (ER), or office visit claim for COPD between January 1, 2012, and November 30, 2013, and continuous enrollment for 1 year before and 2 years after the first COPD diagnosis date. Patients with a spirometry claim within 12 months were eligible for medical record abstraction to confirm COPD diagnosis (forced expiratory volume in 1 second [FEV1]/forced vital capacity ratio < 0.7) and GOLD 1-4 classification (based on postbronchodilator FEV1 percent predicted). HCRU, costs, treatment patterns, and rate of moderate/severe exacerbation were identified from diagnosis up to 24 months. Outcomes were analyzed by univariate analysis stratified by GOLD classification. Multivariable analysis was conducted to assess associations between GOLD classification and outcomes of interest. 53,484 patients newly diagnosed with COPD were identified who met initial inclusion criteria: 14,293 (27%) had a qualifying spirometry claim, and 1,505 had confirmed COPD (GOLD 1, 333 [22%]; GOLD 2, 823 [55%]; GOLD 3, 317 [21%]; GOLD 4, 32 [2%]). Patients with greater disease severity had higher rates of moderate/severe COPD exacerbations (GOLD 1 and 2, 40.4 and 48.9 per 100 person-years, respectively; GOLD 3 and 4, 83.6 and 89.1 per 100 person-years, respectively). All-cause and COPD-related inpatient admissions, COPD-related office visits, and COPD-related ER visits were more prevalent with more severe GOLD classification. Mean annual COPD-related medical costs increased with GOLD classification ($5,945 for GOLD 1 patients, $18,070 for GOLD 4). COPD maintenance medication was filled by 42%, 56%, 73%, and 75% of patients in GOLD 1-4 (57% overall), respectively; combination corticosteroid/long-acting beta2-agonist inhalers were the most commonly used medication, regardless of GOLD classification. Patients with more severe disease had greater adherence (range 44%-68% of days covered for GOLD 1-4) and persistence (range 107-209 days for GOLD 1-4). Trends toward increases in exacerbations, HCRU, and costs were observed as airflow limitation worsened. Adherence and persistence with COPD maintenance therapy was suboptimal even with severe disease. This study was supported by Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT), which was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Willey and Singer are employees of HealthCore (parent company Anthem), which received funding from Boehringer Ingelheim to complete this study. Wallace and Shinde were employed by HealthCore at the time of this study. Wallace and Singer report stock ownership in Anthem. Napier is an employee of Anthem. Kaila, Bayer, and Shaikh are employees of Boehringer Ingelheim Pharmaceuticsls. Portions of this research were presented at the following conferences: (a) A. Wallace, S. Kaila, V. Zubek, A. Shaikh, M. Shinde, V. Willey, M. Napier, and J. Singer, Healthcare resource utilization, costs, and exacerbation rates in patients with COPD stratified by GOLD airflow limitation classification in a US commercially insured population, presented at AMCP Nexus 2017; October 16-19, 2017; Dallas, TX; and (b) A.E. Wallace, V. Zubek, S. Kaila, A. Shaikh, M. Shinde, V. Willey, M.B. Napier, and J.R. Singer, Real-world treatment patterns among newly diagnosed COPD patients according to GOLD airflow limitation severity classification in a U.S. commercially insured/Medicare Advantage population, presented at CHEST 2017 Annual Meeting; October 28-November 1, 2017; Toronto, Ontario, Canada.
- 1 February 2019
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 25 (2) , 205-217
Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and is associated with substantial economic burden. There is a lack of data regarding COPD outcomes and costs in a real-world setting, particularly by Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity. To (a) characterize a commercially insured U.S. population with COPD and (b) assess prevalence of exacerbations, health care resource utilization (HCRU), costs, and treatment patterns in a cohort of patients with confirmed COPD, overall and stratified by GOLD stage. This retrospective observational cohort study used administrative claims data from the HealthCore Integrated Research Database to identify patients with ≥ 1 inpatient, emergency room (ER), or office visit claim for COPD between January 1, 2012, and November 30, 2013, and continuous enrollment for 1 year before and 2 years after the first COPD diagnosis date. Patients with a spirometry claim within 12 months were eligible for medical record abstraction to confirm COPD diagnosis (forced expiratory volume in 1 second [FEV1]/forced vital capacity ratio < 0.7) and GOLD 1-4 classification (based on postbronchodilator FEV1 percent predicted). HCRU, costs, treatment patterns, and rate of moderate/severe exacerbation were identified from diagnosis up to 24 months. Outcomes were analyzed by univariate analysis stratified by GOLD classification. Multivariable analysis was conducted to assess associations between GOLD classification and outcomes of interest. 53,484 patients newly diagnosed with COPD were identified who met initial inclusion criteria: 14,293 (27%) had a qualifying spirometry claim, and 1,505 had confirmed COPD (GOLD 1, 333 [22%]; GOLD 2, 823 [55%]; GOLD 3, 317 [21%]; GOLD 4, 32 [2%]). Patients with greater disease severity had higher rates of moderate/severe COPD exacerbations (GOLD 1 and 2, 40.4 and 48.9 per 100 person-years, respectively; GOLD 3 and 4, 83.6 and 89.1 per 100 person-years, respectively). All-cause and COPD-related inpatient admissions, COPD-related office visits, and COPD-related ER visits were more prevalent with more severe GOLD classification. Mean annual COPD-related medical costs increased with GOLD classification ($5,945 for GOLD 1 patients, $18,070 for GOLD 4). COPD maintenance medication was filled by 42%, 56%, 73%, and 75% of patients in GOLD 1-4 (57% overall), respectively; combination corticosteroid/long-acting beta2-agonist inhalers were the most commonly used medication, regardless of GOLD classification. Patients with more severe disease had greater adherence (range 44%-68% of days covered for GOLD 1-4) and persistence (range 107-209 days for GOLD 1-4). Trends toward increases in exacerbations, HCRU, and costs were observed as airflow limitation worsened. Adherence and persistence with COPD maintenance therapy was suboptimal even with severe disease. This study was supported by Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT), which was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Willey and Singer are employees of HealthCore (parent company Anthem), which received funding from Boehringer Ingelheim to complete this study. Wallace and Shinde were employed by HealthCore at the time of this study. Wallace and Singer report stock ownership in Anthem. Napier is an employee of Anthem. Kaila, Bayer, and Shaikh are employees of Boehringer Ingelheim Pharmaceuticsls. Portions of this research were presented at the following conferences: (a) A. Wallace, S. Kaila, V. Zubek, A. Shaikh, M. Shinde, V. Willey, M. Napier, and J. Singer, Healthcare resource utilization, costs, and exacerbation rates in patients with COPD stratified by GOLD airflow limitation classification in a US commercially insured population, presented at AMCP Nexus 2017; October 16-19, 2017; Dallas, TX; and (b) A.E. Wallace, V. Zubek, S. Kaila, A. Shaikh, M. Shinde, V. Willey, M.B. Napier, and J.R. Singer, Real-world treatment patterns among newly diagnosed COPD patients according to GOLD airflow limitation severity classification in a U.S. commercially insured/Medicare Advantage population, presented at CHEST 2017 Annual Meeting; October 28-November 1, 2017; Toronto, Ontario, Canada.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18003
Validity of clinical information for a novel cancer care quality program.
E18003 Background: Through Anthem’s Cancer Care Quality Program (CCQP), oncologists can submit requests and accompanying clinical rationale for cancer treatments. Qualifying treatments within evidence-based pathways are eligible for enhanced reimbursement. The accuracy of clinical information within the CCQP is vital to the program’s overall effectiveness. This study evaluated the validity of the clinical information submitted to the CCQP compared with medical records of lung cancer patients obtained from treating providers. Methods: Data elements obtained relevant to this study include cancer type, stage, histology, and biomarkers (ie, ALK and EGFR mutation status). A sample of 200 lung cancer patients with CCQP requests for treatment within the HealthCore Integrated Research Environment (HIRE) – Oncology data were identified for medical record collection and review by a blinded board certified oncology pharmacist. Statistical measures of validity (agreement, positive & negative predictive value (PPV & NPV), sensitivity, and specificity) were used to compare clinical information between data sources. Results: Approximately 1300 patients with lung cancer were identified in the first year of the program (Jul 2014 – Jun 2015). Of the 200 records reviewed, 197 were confirmed to be lung cancer (PPV of 0.99) and 87% were identified as non-small cell lung cancer (NSCLC). All performance measures were ≥ 0.85, with the exception of the PPV for ALK status. Conclusions: Overall, the high agreement between the data entered for the CCQP and medical records support the validity of the clinical information for purposes of effective program implementation, administration, and research.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18003
Validity of clinical information for a novel cancer care quality program.
E18003 Background: Through Anthem’s Cancer Care Quality Program (CCQP), oncologists can submit requests and accompanying clinical rationale for cancer treatments. Qualifying treatments within evidence-based pathways are eligible for enhanced reimbursement. The accuracy of clinical information within the CCQP is vital to the program’s overall effectiveness. This study evaluated the validity of the clinical information submitted to the CCQP compared with medical records of lung cancer patients obtained from treating providers. Methods: Data elements obtained relevant to this study include cancer type, stage, histology, and biomarkers (ie, ALK and EGFR mutation status). A sample of 200 lung cancer patients with CCQP requests for treatment within the HealthCore Integrated Research Environment (HIRE) – Oncology data were identified for medical record collection and review by a blinded board certified oncology pharmacist. Statistical measures of validity (agreement, positive & negative predictive value (PPV & NPV), sensitivity, and specificity) were used to compare clinical information between data sources. Results: Approximately 1300 patients with lung cancer were identified in the first year of the program (Jul 2014 – Jun 2015). Of the 200 records reviewed, 197 were confirmed to be lung cancer (PPV of 0.99) and 87% were identified as non-small cell lung cancer (NSCLC). All performance measures were ≥ 0.85, with the exception of the PPV for ALK status. Conclusions: Overall, the high agreement between the data entered for the CCQP and medical records support the validity of the clinical information for purposes of effective program implementation, administration, and research.
- 29 July 2010
- Published by Wiley in Academic Emergency Medicine
- Vol. 17 (8) , 824-833
Efficiency and Economic Benefits of a Payer‐based Electronic Health Record in an Emergency Department
The objective was to evaluate the use of a payer-based electronic health record (P-EHR), which is a clinical summary of a patient's medical and pharmacy claims history, in an emergency department (ED) on length of stay (LOS) and plan payments. A large urban ED partnered with the dominant health plan in the region and implemented P-EHR technology in September 2005 for widespread use for health plan members presenting to the ED. A retrospective observational study design was used to evaluate this previously implemented P-EHR. Health plan and electronic hospital data were used to identify 2,288 ED encounters. Encounters with P-EHR use (n = 779) were identified between September 1, 2005, and February 17, 2006; encounters from the same health plan (n = 1,509) between November 1, 2004, and March 31, 2005, were compared. Outcomes were ED LOS and plan payment for the ED encounter. Analyses evaluated the effect of using the P-EHR in the ED setting on study outcomes using multivariate regressions and the nonparametric bootstrap. After covariate adjustment, among visits resulting in discharge (ED-only), P-EHR visits were 19 minutes shorter (95% confidence interval [CI] = 5 to 33 minutes) than non-P-EHR visits. Among visits resulting in hospitalization, the P-EHR was associated with an average 77-minute shorter ED LOS (95% CI = 28 to 126 minutes), compared to non-P-EHR visits. The P-EHR was associated with an average of $1,560 (95% CI = $43 to $2,910) lower total plan expenditures for hospitalized visits. No significant difference in total payments was observed among discharged visits. In the study ED, the P-EHR was associated with a significant reduction in ED LOS overall and was associated with lower plan payments for visits that resulted in hospitalization.
- 29 July 2010
- Published by Wiley in Academic Emergency Medicine
- Vol. 17 (8) , 824-833
Efficiency and Economic Benefits of a Payer‐based Electronic Health Record in an Emergency Department
The objective was to evaluate the use of a payer-based electronic health record (P-EHR), which is a clinical summary of a patient's medical and pharmacy claims history, in an emergency department (ED) on length of stay (LOS) and plan payments. A large urban ED partnered with the dominant health plan in the region and implemented P-EHR technology in September 2005 for widespread use for health plan members presenting to the ED. A retrospective observational study design was used to evaluate this previously implemented P-EHR. Health plan and electronic hospital data were used to identify 2,288 ED encounters. Encounters with P-EHR use (n = 779) were identified between September 1, 2005, and February 17, 2006; encounters from the same health plan (n = 1,509) between November 1, 2004, and March 31, 2005, were compared. Outcomes were ED LOS and plan payment for the ED encounter. Analyses evaluated the effect of using the P-EHR in the ED setting on study outcomes using multivariate regressions and the nonparametric bootstrap. After covariate adjustment, among visits resulting in discharge (ED-only), P-EHR visits were 19 minutes shorter (95% confidence interval [CI] = 5 to 33 minutes) than non-P-EHR visits. Among visits resulting in hospitalization, the P-EHR was associated with an average 77-minute shorter ED LOS (95% CI = 28 to 126 minutes), compared to non-P-EHR visits. The P-EHR was associated with an average of $1,560 (95% CI = $43 to $2,910) lower total plan expenditures for hospitalized visits. No significant difference in total payments was observed among discharged visits. In the study ED, the P-EHR was associated with a significant reduction in ED LOS overall and was associated with lower plan payments for visits that resulted in hospitalization.
- 16 November 2009
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (1) , 121-128
Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
The availability of generic simvastatin has changed the relative cost structure within the statin marketplace and has been associated with third-party payer changes to formularies and statin utilization policies. The current study examines simvastatin therapy modification patterns and associated low-density lipoprotein cholesterol (LDL-C) goal attainment rates. This retrospective, observational study utilized administrative claims linked to laboratory result data from a national health plan. Patients newly initiated on generic simvastatin from January 2007 to March 2008 were identified. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) risk categories and goal LDL-C targets were assigned. Simvastatin dose titrations and switches to other statins were described, as were changes in LDL-C values and NCEP ATP III goal attainment rates both before and after therapy modifications. Of the 1654 patients newly initiated on simvastatin, 84% had no simvastatin therapy modification in the >1-year follow-up period. For patients with no therapy modification, 54.4% did not achieve their LDL-C NCEP ATP III goal at their first lipid panel and goal attainment was strongly associated with the level of cardiovascular risk (goal attainment rate = 75.1%, 51.7%, and 28.6% for low-, moderate- and high-risk categories, respectively). Of patients not achieving NCEP ATP III LDL-C goals (n = 885), 85.4% had no therapy modification. Goal was achieved after therapy modification in 36% (dose titration) and 42% (switchers); high-risk patients goal attainment rates were 23% and 38%, respectively. Limitations of the study include the observational design, use of an administrative claims database to assess cardiovascular risk, relatively short follow-up time (slightly more than 1 year) and the lack of assessment of adherence to therapy. This study found that the majority of patients initiated on generic simvastatin stayed on their initial starting dose regardless of NCEP ATP III goal attainment status. The findings of low rates of therapy modification irrespective of baseline CV risk and associated low rates of goal attainment, especially in high risk patients treated with simvastatin, indicate an opportunity to encourage clinical decision making based on the needs of the individual patient.
- 16 November 2009
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (1) , 121-128
Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
The availability of generic simvastatin has changed the relative cost structure within the statin marketplace and has been associated with third-party payer changes to formularies and statin utilization policies. The current study examines simvastatin therapy modification patterns and associated low-density lipoprotein cholesterol (LDL-C) goal attainment rates. This retrospective, observational study utilized administrative claims linked to laboratory result data from a national health plan. Patients newly initiated on generic simvastatin from January 2007 to March 2008 were identified. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) risk categories and goal LDL-C targets were assigned. Simvastatin dose titrations and switches to other statins were described, as were changes in LDL-C values and NCEP ATP III goal attainment rates both before and after therapy modifications. Of the 1654 patients newly initiated on simvastatin, 84% had no simvastatin therapy modification in the >1-year follow-up period. For patients with no therapy modification, 54.4% did not achieve their LDL-C NCEP ATP III goal at their first lipid panel and goal attainment was strongly associated with the level of cardiovascular risk (goal attainment rate = 75.1%, 51.7%, and 28.6% for low-, moderate- and high-risk categories, respectively). Of patients not achieving NCEP ATP III LDL-C goals (n = 885), 85.4% had no therapy modification. Goal was achieved after therapy modification in 36% (dose titration) and 42% (switchers); high-risk patients goal attainment rates were 23% and 38%, respectively. Limitations of the study include the observational design, use of an administrative claims database to assess cardiovascular risk, relatively short follow-up time (slightly more than 1 year) and the lack of assessment of adherence to therapy. This study found that the majority of patients initiated on generic simvastatin stayed on their initial starting dose regardless of NCEP ATP III goal attainment status. The findings of low rates of therapy modification irrespective of baseline CV risk and associated low rates of goal attainment, especially in high risk patients treated with simvastatin, indicate an opportunity to encourage clinical decision making based on the needs of the individual patient.
- 1 July 2008
- Vol. 14, S252-63
Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use.
Chronic and severe health problems place an enormous financial burden on individuals, employers, and health plan providers, requiring all to make tough decisions about healthcare. Specialty pharmaceuticals are increasingly attractive treatment options, but employers need tangible ways to incorporate these medications into benefit plans. Benefit managers can take a proactive role in addressing cost and compliance issues, using evidence-based data about true patient costs to develop policies that encourage employees to seek appropriate care. Achieving savings in direct and indirect costs will require more than shifting coverage, which can lead to nonadherence and increase costs elsewhere.
- 1 July 2008
- Vol. 14, S252-63
Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use.
Chronic and severe health problems place an enormous financial burden on individuals, employers, and health plan providers, requiring all to make tough decisions about healthcare. Specialty pharmaceuticals are increasingly attractive treatment options, but employers need tangible ways to incorporate these medications into benefit plans. Benefit managers can take a proactive role in addressing cost and compliance issues, using evidence-based data about true patient costs to develop policies that encourage employees to seek appropriate care. Achieving savings in direct and indirect costs will require more than shifting coverage, which can lead to nonadherence and increase costs elsewhere.
- 1 May 2008
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 27 (3) , 824-834
Costs Of Severely Ill Members And Specialty Medication Use In A Commercially Insured Population
This study examines the overall profile and costs associated with severely ill commercially insured people. We found severely ill members to have the highest costs, from both the insurer and member perspective. Even for the most costly members where specialty medication use was highest, biologics represented less than one-third of the pharmacy spending and 6.6 percent of overall spending. Out-of-pocket spending rose dramatically when medications were paid for under the pharmacy benefit rather than the medical benefit. The advantages of paying for specialty medications under the pharmacy benefit should be evaluated in conjunction with the potential consequences of increased out-of-pocket burden.
- 1 May 2008
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 27 (3) , 824-834
Costs Of Severely Ill Members And Specialty Medication Use In A Commercially Insured Population
This study examines the overall profile and costs associated with severely ill commercially insured people. We found severely ill members to have the highest costs, from both the insurer and member perspective. Even for the most costly members where specialty medication use was highest, biologics represented less than one-third of the pharmacy spending and 6.6 percent of overall spending. Out-of-pocket spending rose dramatically when medications were paid for under the pharmacy benefit rather than the medical benefit. The advantages of paying for specialty medications under the pharmacy benefit should be evaluated in conjunction with the potential consequences of increased out-of-pocket burden.